Literature DB >> 9882031

Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors.

P O Katz1, C Anderson, R Khoury, D O Castell.   

Abstract

BACKGROUND: Nocturnal gastric acid breakthrough, defined as intragastric pH < 4 for more than 1 h in the overnight period, is observed in up to 70% of normal subjects on proton pump inhibitors taken twice daily. The frequency of this breakthrough in patients with gastro-oesophageal reflux and accompanying oesophageal reflux during this period has not been studied. AIM: To examine the frequency of nocturnal break-through and accompanying oesophageal acid exposure in patients with gastro-oesophageal reflux treated with proton pump inhibitors twice daily.
METHODS: Prolonged ambulatory pH records from 76 patients on twice daily proton pump inhibitors between January 1991 and July 1997 were analysed for the presence of nocturnal gastric acid breakthrough and accompanying oesophageal pH < 4. Studies from 31 normal subjects on twice daily proton pump inhibitors constituted the control group.
RESULTS: Nocturnal gastric acid breakthrough was seen in 70% of 61 patients with gastro-oesophageal reflux, 80% of 15 patients with Barrett's oesophagus and 67% of normal controls (P=N.S.). Oesophageal acid exposure was seen in 33% of gastro-oesophageal reflux patients, 50% of Barrett's oesophagus patients and 8% of normal controls (P < 0.03). No difference was found between patients taking omeprazole or lansoprazole.
CONCLUSION: Nocturnal acid breakthrough is frequently seen on proton pump inhibitors twice daily and is often accompanied by oesophageal reflux. This has important implications for medical therapy in patients with severe gastro-oesophageal reflux and Barrett's oesophagus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9882031     DOI: 10.1046/j.1365-2036.1998.00419.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  30 in total

Review 1.  Medical treatment of Barrett's esophagus.

Authors:  S J Spechler
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

2.  [Barrett esophagus: epidemiology, incidence of carcinoma, need for screening].

Authors:  R Arnold; M Wied
Journal:  Internist (Berl)       Date:  2003-01       Impact factor: 0.743

3.  Inhibitory potency of twice-a-day omeprazole on gastric acidity is enhanced by eradication of H. pylori in duodenal ulcer patients.

Authors:  A B R Thomson; M Keelan; R Lastiwka; S Appelman-Eszczuk; L Zuk; L Drozdowski; A Prentice; P Sinclair
Journal:  Dig Dis Sci       Date:  2003-10       Impact factor: 3.199

4.  Nocturnal acid breakthrough on proton pump inhibitor therapy: to treat or not to treat.

Authors:  Philip O Katz; Robert S Dudnick
Journal:  Curr Treat Options Gastroenterol       Date:  2008-02

5.  New method for long-term monitoring of intragastric pH.

Authors:  Shouko Ono; Mototsugu Kato; Yuji Ono; Masahiro Asaka
Journal:  World J Gastroenterol       Date:  2007-12-21       Impact factor: 5.742

Review 6.  Barrett's oesophagus: the new endoscopic modalities have a future.

Authors:  J Deviere
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

7.  Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism.

Authors:  Horng-Yuan Lou; Chun-Chao Chang; Ming-Thau Sheu; Ying-Chen Chen; Hsiu-O Ho
Journal:  Eur J Clin Pharmacol       Date:  2008-08-27       Impact factor: 2.953

Review 8.  Guide to the use of proton pump inhibitors in adult patients.

Authors:  Vandana Boparai; Jaishree Rajagopalan; George Triadafilopoulos
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Monitoring for GE Reflux: Is Normal the New Normal?

Authors:  Mustafa Abdul-Hussein; Donald O Castell
Journal:  Dig Dis Sci       Date:  2015-05       Impact factor: 3.199

Review 10.  Step-up and step-down approaches to treatment of gastroesophageal reflux disease in children.

Authors:  Eric Hassall
Journal:  Curr Gastroenterol Rep       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.